BME:ORYBiotechs
Oryzon Genomics (BME:ORY) Losses Narrowing Tests Bullish Profitability Narratives
Oryzon Genomics (BME:ORY) has opened 2026 earnings season with Q1 numbers that sit against a backdrop of quarterly revenue of €12.8 million and a basic EPS loss of €0.02 in Q4 2025. Over the last reported periods, the company has seen quarterly revenue move between €4.97 million and €12.8 million, while basic EPS has remained in loss-making territory in both euro and US dollar terms. With forecasts pointing to changes in revenue and EPS alongside an expected shift toward profitability within...